Tivozanib
CAS 475108-18-0 6 FDA-DMF suppliersSmall Molecule
Overview
Tivozanib is a potent and selective inhibitor of vascular endothelial growth factor receptors (VEGFRs), designed to inhibit angiogenesis for the treatment of renal cell carcinoma. It is effective in blocking tumor angiogenesis, thereby reducing blood supply to the tumor.
Patent & exclusivity (US)
Per the FDA Orange Book (2 approved US products), the latest listed US patent on Tivozanib expires 5 Nov 2039 and exclusivity 10 Mar 2026. Generic API sourcing typically opens up once these lapse.
Therapeutic areas
OncologyRenal Cell CarcinomaSolid Tumors
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.